Drutz David
Known title: DirectorCIK: 0001428764
Drutz David's purchase track record
How the stock did after each of Drutz David's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
4
of 4 since May 24, 2022
Stock higher 6 months later
75%
3 months: 50%
Median 6-month return
+63.4%
3 months: +39.0%
Beat the S&P 500
75%
median +59.9% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/15/2023 | ALT | $863 | -14.2% | +201.1% | +11.6% |
| 3/23/2023 | ALT | $38K | -0.7% | -38.9% | +9.7% |
| 6/15/2022 | ALT | $8K | +78.7% | +29.6% | +5.4% |
| 5/24/2022 | ALT | $5K | +290.5% | +97.3% | +1.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ALT | ▲ Buy | Option Exercise | 20,000 | $52K | 8/19/2024 | View on chart |
| ALT | ▼ Sell | Open Market | 8,184 | $56K | 8/19/2024 | View on chart |
| ALT | ▼ Sell | Open Market | 7,827 | $54K | 8/19/2024 | View on chart |
| ALT | ▲ Buy | Option Exercise | 21,750 | $54K | 8/19/2024 | View on chart |
| ALT | ▲ Buy | Open Market | 300 | $863 | 8/15/2023 | View on chart |
| ALT | ▲ Buy | Open Market | 9,000 | $38K | 3/23/2023 | View on chart |
| ALT | ▲ Buy | Option Exercise | 139 | $334 | 11/18/2022 | View on chart |
| ALT | ▲ Buy | Open Market | 1,000 | $8K | 6/15/2022 | View on chart |
| ALT | ▲ Buy | Open Market | 1,200 | $5K | 5/24/2022 | View on chart |
| ALT | ▲ Buy | Option Exercise | 70 | $168 | 1/25/2022 | View on chart |
| ALT | ▲ Buy | Option Exercise | 139 | $334 | 12/14/2021 | View on chart |
| ALT | ▲ Buy | Option Exercise | 70 | $168 | 11/19/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Altimmune to attend Wells Fargo healthcare conference
Altimmune has been confirmed as a participant in the Wells Fargo 21st Annual Healthcare Conference. The company joins a roster of healthcare firms presenting at the event, which is a common venue for biopharma companies to engage with investors and outline pipeline progress. No new clinical, regulatory, or financial announcements accompanied the participation news, so the development is a routine scheduling item rather than a fundamental catalyst. As context, the stock has been trading well below the average analyst price target of $17.22, with its 52-week range between $2.56 and $6.44.
Altimmune to attend Wells Fargo healthcare conference. Altimmune has been confirmed as a participant in the Wells Fargo 21st Annual Healthcare Conference. The company joins a roster of healthcare firms presenting at the event, which is a common venue for biopharma companies to engage with investors and outline pipeline progress. No new clinical, regulatory, or financial announcements accompanied the participation news, so the development is a routine scheduling item rather than a fundamental catalyst. As context, the stock has been trading well below the average analyst price target of $17.22, with its 52-week range between $2.56 and $6.44.